PRO DEX Inc. (PDEX)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 788920 · fiscal year ends in Jun
Closing price $58.06 on 30 Oct 2026; 52-week range $28.91 to $73.41.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $79.6M
- Revenue growth
- 13.3%
- Net income, last twelve months
- $12.0M
- Earnings per share
- $3.64
- Gross margin
- 32.5%
- Operating margin
- 16.8%
- Net margin
- 15.1%
- Free cash flow
- $10.7M
- Return on equity
- 24.4%
- Market value
- $186.0M
- Price to earnings
- 16.0x
- Cash
- $11.8M
- Debt
- $16.4M
- Debt to equity
- 0.33
- Shares outstanding
- 3.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2026 | 30 Jun 2026 | $77.5M | $13.0M | $13.7M | $4.12 | $6.8M | 10-K filed 3 Sep 2026 |
| FY2025 | 30 Jun 2025 | $66.6M | $10.7M | $9.0M | $2.67 | -$2.9M | 10-K filed 4 Sep 2025 |
| FY2024 | 30 Jun 2024 | $53.8M | $7.2M | $2.1M | $0.60 | – | 10-K filed 5 Sep 2024 |
| FY2023 | 30 Jun 2023 | $46.1M | $5.8M | $7.1M | $1.95 | – | 10-K filed 13 Oct 2023 |
| FY2022 | 30 Jun 2022 | $42.0M | $5.1M | $4.6M | $1.21 | -$2.5M | 10-K filed 8 Sep 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q1 FY2027 | 30 Sep 2026 | $20.6M | $3.0M | $0.92 |
| Q4 FY2026 | 30 Jun 2026 | $20.4M | $2.9M | $0.86 |
| Q3 FY2026 | 31 Mar 2026 | $19.9M | $3.9M | $1.20 |
| Q2 FY2026 | 31 Dec 2025 | $18.7M | $2.2M | $0.66 |
| Q1 FY2026 | 30 Sep 2025 | $18.5M | $4.7M | $1.40 |
| Q4 FY2025 | 30 Jun 2025 | $17.5M | $1.2M | $0.37 |
| Q3 FY2025 | 31 Mar 2025 | $17.4M | $3.3M | $0.98 |
| Q2 FY2025 | 31 Dec 2024 | $16.8M | $2.0M | $0.61 |
Company events
The newest 8-K filings of 253 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 30 Oct 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 29 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 18 Sep 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 3 Sep 2026 | 8-K | Results | 2.02, 9.01 |
| 28 Aug 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 17 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 30 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 27 Mar 2026 | 8-K | Leadership change | 5.02 |
| 12 Feb 2026 | 8-K | Deal completed, Material agreement, New debt, Investor update | 1.01, 2.01, 2.03, 7.01, 9.01 |
| 29 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 19 Dec 2025 | 8-K | Leadership change, Other events | 5.02, 8.01, 9.01 |
| 21 Nov 2025 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
Every filing
The newest filings with the SEC of 573 held.
| Filed | Form | Period |
|---|---|---|
| 30 Oct 2026 | 8-K | 26 Oct 2026 |
| 29 Oct 2026 | 8-K | 29 Oct 2026 |
| 29 Oct 2026 | 10-Q | 30 Sep 2026 |
| 6 Oct 2026 | ARS | 30 Jun 2026 |
| 6 Oct 2026 | DEFA14A | – |
| 6 Oct 2026 | DEF 14A | 19 Nov 2026 |
| 18 Sep 2026 | 8-K | 16 Sep 2026 |
| 3 Sep 2026 | 8-K | 3 Sep 2026 |
| 3 Sep 2026 | 10-K | 30 Jun 2026 |
| 28 Aug 2026 | 8-K | 26 Aug 2026 |
| 17 Jun 2026 | 8-K | 17 Jun 2026 |
| 1 Jun 2026 | SD | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 11 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 290 | $58.94 | $17.1K | 79,703 | 14 Sep 2026 |
| 11 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 475 | $59.62 | $28.3K | 79,228 | 14 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 2,160 | $58.92 | $127.3K | 97,068 | 10 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 2,691 | $59.84 | $161.0K | 94,377 | 10 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 4,274 | $60.72 | $259.5K | 90,103 | 10 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 1,157 | $61.88 | $71.6K | 88,946 | 10 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 935 | $62.93 | $58.8K | 88,011 | 10 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 2,144 | $63.85 | $136.9K | 85,867 | 10 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 300 | $64.70 | $19.4K | 85,567 | 10 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 806 | $58.66 | $47.3K | 84,761 | 10 Sep 2026 |
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Chief Executive Officer | Sale under a trading plan | 4,768 | $59.45 | $283.5K | 79,993 | 10 Sep 2026 |
| 9 Sep 2026 | Charlton Alisha, Chief Financial Officer | Sale outside a trading plan | 1,500 | $61.05 | $91.6K | 22,670 | 10 Sep 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 9 Sep 2026 | Van Kirk Richard Lee Jr, Officer, Director | 20,000 | $1.3M | 9 Sep 2026 |
| 8 Sep 2026 | Alisha Charlton, Chief Financial Officer | 2,300 | $168.8K | 9 Sep 2026 |
| 21 May 2026 | Van Kirk Richard Lee Jr, Officer, Director | 10,000 | $628.4K | 21 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 26 Jun 2026 | AO Partners I, L.P. | 13D amended | 31.88% | 1.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 235.9K | +18.32% | 4.95 |
| 30 Sep 2026 | 199.4K | -5.01% | 2.89 |
| 15 Sep 2026 | 209.9K | +17.4% | 2.29 |
| 31 Aug 2026 | 178.8K | -7.92% | 3.72 |
| 14 Aug 2026 | 194.2K | +13.75% | 2.05 |
| 31 Jul 2026 | 170.7K | +8.69% | 1.71 |
| 15 Jul 2026 | 157.1K | +5.67% | 1.62 |
| 30 Jun 2026 | 148.6K | -9.98% | 1.71 |
Funds that hold it
From each fund's latest Form 13F.
73 funds held it at 30 Jun 2026: 38 added and 19 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 153,178 | $9.0M | +663 |
| Vanguard Capital Management LLC | 82,283 | $4.8M | -29,047 |
| Dimensional Fund Advisors LP | 57,061 | $3.3M | +120 |
| Punch & Associates Investment Management, Inc. | 52,735 | $3.1M | -9,000 |
| Geode Capital Management, LLC | 49,636 | $2.9M | +1,289 |
| JPMorgan Chase & Co. | 32,287 | $1.9M | +251 |
| State Street Corp. | 31,310 | $1.8M | -1,804 |
| Goldman Sachs Group Inc. | 18,711 | $1.1M | +8,570 |
| Pekin Hardy Strauss, Inc. | 16,500 | $966.1K | +16,500 |
| BNP Paribas Financial Markets | 15,945 | $933.6K | +2,711 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B